Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists

Chronic ITP, ITP, thrombopoietin, new agents, New Drugs, Refractory ITP

REFERENCES:
1. Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012;38:454–62
2. Audia S and Bonnotte B. Emerging therapies in Immune Thrombocytopenia. J. Clin. Med. 2021, 10, 1004
3. Miltiadous O, Hou M, Bussel JB, Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood 2020;135(7):472-490
4. Cooper N, Kruse A, Kruse C, Watson S, Morgan M et al Immune thrombocytopenia (ITP) World Impact Survey (I-WISh): Impact of ITP on health-related quality of life. Am J Hem 2021 Feb 1;96(2):199-207.doi: 10.1002/ajh.26036
5. Ulrichts P et al. Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans J Clin Invest 2018 Oct 1;128(10):4372-4386
6. Broome C, McDonald V, Miyakawa Y, Carpenedo, M et al. Efficacy and Safety of Intravenous Efgartigimod in Adults with Primary ITP: Results of ADVANCE IV, a Phase 3, Multicenter, Double blinded, Placebo-controlled, Randomized Clinical Trial , 64th ASH Annual Meeting, New Orleans, 10-13th December 2022
7. Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104:1112–23.
8. Schifferli A et al. Immunomodulation in Primary immune Trhombocytopenia: a possible role of the Fc fragment of romiplostim? ) Front Imm 2019; 10: 1196
9. De Groot A et al. Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction. Sci Rep 2019 Nov 6;9(1):16103
10. Blumberg RS, Lillicrap D, IgG Fc Immune Tolerance Group. Tolerogenic properties of the Fc portion of IgG and its relevance to the treatment and management of hemophilia. Blood. (2018) 131:2205–14